About: Therapeutic Delivery of Ang(1–7) via Genetically Modified Probiotic: A Dosing Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Therapeutic Delivery of Ang(1–7) via Genetically Modified Probiotic: A Dosing Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Therapeutic Delivery of Ang(1–7) via Genetically Modified Probiotic: A Dosing Study
Creator	Li, Qiuhong Raizada, Mohan Aquino, Victor Buford, Thomas Carter, Christy Lobaton, Gilberto Morgan, Drake Sumners, Elaine Verma, Amrisha
Source	PMC
abstract	In recent years a number of beneficial health effects have been ascribed to the renin-angiotensin system (RAS) that extend beyond lowering blood pressure, primarily mediated via the angiotensin-converting enzyme-2 (ACE2)/angiotensin (1–7) or Ang(1–7)/MAS receptor axis. Moreover, once thought as merely a systemic effector, RAS components exist within tissues. The highest tissue concentrations of ACE2 mRNA are located in the gut making it an important target for altering RAS function. Indeed, genetically engineered recombinant probiotics are promising treatment strategies offering delivery of therapeutic proteins with precision. An Ang(1–7) secreting Lactobacillus paracasei (LP) or LP-A has been described for regulation of diabetes and hypertension; however, we are the first to the best of our knowledge to propose this paradigm as it relates to aging. In this Research Practice manuscript, we provide proof of concept for using this technology in a well-characterized rodent model of aging: the Fisher344 x Brown Norway Rat (F344BN). Our primary findings suggest that LP-A increases circulating levels of Ang(1–7) both acutely and chronically (after 8 or 28 treatment days) when administered 3× or 7×/week over 4 weeks. Our future preclinical studies will explore the impact of this treatment on gut and other age-sensitive distal tissues such as brain and muscle.
has issue date	2019-10-05(xsd:dateTime)
bibo:doi	10.1093/gerona/glz222
bibo:pmid	31586210
has license	no-cc
sha1sum (hex)	108a1352cb1011f76444a62642d715f04a4f2d14
schema:url	https://doi.org/10.1093/gerona/glz222
resource representing a document's title	Therapeutic Delivery of Ang(1–7) via Genetically Modified Probiotic: A Dosing Study
has PubMed Central identifier	PMC7109904
has PubMed identifier	31586210
schema:publication	J Gerontol A Biol Sci Med Sci
resource representing a document's body	covid:108a1352cb1011f76444a62642d715f04a4f2d14#body_text
is schema:about of	named entity 'CITE' named entity 'strategies' named entity 'RAS' named entity 'gut' named entity 'EFFECTOR' named entity 'ADMINISTERED' named entity 'PROOF OF CONCEPT' named entity 'BRAIN' named entity 'INCREASES' named entity 'DESCRIBED' named entity 'TREATMENT' named entity 'RODENT MODEL' named entity 'CIRCULATING' named entity 'THE GUT' named entity 'AXIS' named entity 'GUT' named entity 'HIGHEST' named entity '4 WEEKS' named entity 'DAYS' named entity 'SYSTEMIC' named entity 'BEYOND' named entity 'EXIST' named entity 'RELATES' named entity 'RECOMBINANT' named entity 'RESEARCH PRACTICE' named entity 'ALTERING' named entity 'ACE2' named entity 'AGE' named entity 'PARADIGM' named entity 'PRECISION' named entity 'COMPONENTS' named entity 'BLOOD PRESSURE' named entity 'HYPERTENSION' named entity 'PROBIOTICS' named entity 'FUTURE' named entity 'ANG' named entity 'MRNA' named entity 'PROVIDE' named entity 'OUR' named entity 'TISSUE' named entity 'PRIMARY' named entity 'RENIN-ANGIOTENSIN SYSTEM' named entity 'AGING' named entity 'NUMBER OF' named entity 'USING' named entity 'LACTOBACILLUS PARACASEI' named entity 'MEDIATED' named entity 'MUSCLE' named entity 'HAVE' named entity 'IMPORTANT' named entity 'YEARS' named entity 'LOCATED IN' named entity 'KNOWLEDGE' named entity 'TISSUES' named entity 'LEVELS' named entity 'FINDINGS' named entity 'RAS' named entity 'TARGET' named entity 'DELIVERY' named entity 'SUGGEST' named entity 'CHRONICALLY' named entity 'THOUGHT' named entity 'RECEPTOR' named entity 'STRATEGIES' named entity 'HEALTH' named entity 'SENSITIVE' named entity 'RECENT' named entity 'THERAPEUTIC PROTEINS' named entity 'EXTEND' named entity 'BROWN NORWAY RAT' named entity 'REGULATION' named entity 'SECRETING' named entity 'DIABETES'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software